MALVERN, Pa.–(BUSINESS WIRE)–NexEos Bio Vision Health (“NexEos”), a clinical-stage biopharmaceutical company developing novel therapies and diagnostics targetingMALVERN, Pa.–(BUSINESS WIRE)–NexEos Bio Vision Health (“NexEos”), a clinical-stage biopharmaceutical company developing novel therapies and diagnostics targeting

NexEos Bio Announces FDA Clearance of IND Application to Proceed to Phase II/III Trial of NTX-1024 in Vernal Keratoconjunctivitis

2026/02/20 00:01
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

MALVERN, Pa.–(BUSINESS WIRE)–NexEos Bio Vision Health (“NexEos”), a clinical-stage biopharmaceutical company developing novel therapies and diagnostics targeting eosinophil-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared NexEos’s Investigational New Drug (IND) Application to proceed to a Phase II/III clinical trial of NTX-1024 for the treatment of patients with the rare disease, vernal keratoconjunctivitis (VKC). The planned Phase II/III trial is a single, randomized, double-masked, vehicle-controlled trial to evaluate the safety and efficacy of NTX-1024 ophthalmic solution in patients with VKC.

This is on the heels of the positive results reported from an open-label, investigator-initiated study evaluating the efficacy, safety, and tolerability of NTX-1024 eye drops in adults with VKC. The study was conducted in Mexico and enrolled 15 patients with mild to moderate VKC who received NTX-1024 four times daily over a four-week period. Treatment led to significant improvement in patient-reported symptoms such as itching and quality of life, along with reductions in clinical signs of inflammation, including hyperemia and corneal fluorescein staining. NTX-1024 was also found to be safe and well-tolerated.

This marks the first clinical study to evaluate NTX-1024 in VKC, a rare and severe eosinophil-driven ocular condition that can lead to irreversible ocular damage, including vision loss, if left untreated. These results reinforce the therapeutic potential of NTX-1024 in VKC and have prompted NexEos to pursue further clinical development.

In addition, on January 16, 2026, the FDA granted Orphan Drug Designation to NTX-1024 for VKC.

“Clearance of our IND application, which included data from our open-label investigator-initiated study in Mexico, is an important and meaningful step for the program,” said Steve Tullman, CEO and Chairman of NexEos. “We are excited to advance clinical development of NTX-1024, which would be the first, ophthalmic therapeutic to neutralizes eosinophil cationic protein to reduce inflammation in rare forms of Allergic Conjunctivitis – Vernal Keratoconjunctivitis (VKC) and Atopic Keratoconjunctivitis (AKC). We are on track to initiate our Phase II/III clinical trial by the second half of this year, taking us closer to our objective of delivering a best-in-class therapeutic option to patients with VKC.”

About Vernal Keratoconjunctivitis (VKC)

VKC is a rare, chronic, and vision-threatening ocular inflammatory disease that is predominantly eosinophil-mediated. Activated eosinophils release toxic granule proteins, including eosinophil major basic protein-1 (eMBP1), resulting in damage to the ocular surface (Sacchetti, et al. 2021). VKC primarily affects children although approximately 10% of cases persist into adulthood (Di Zazzo A 2024). Uncontrolled VKC can result in severe ocular damage and permanent vision loss (Vichyanond, et al. 2014).

About NTX-1024 (gleceparin sodium)

NTX-1024 is a novel, topical ophthalmic solution targeting eosinophil cationic protein mediated inflammation in rare forms of allergic conjunctivitis, including VKC and AKC. NTX-1024 has completed proof of concept in VKC, received ODD approval, and now has FDA clearance of its IND application to advance to a Phase II/III clinical trial in VKC. NTX-1024 is the first therapeutic successfully targeting neutralization of eosinophil cationic proteins. Finally, NTX-1024 has the potential to be the first drug to be disease-modifying and steroid-sparing in VKC and AKC.

About NexEos Bio

NexEos Bio (www.nexeosbio.com) is a privately held medical diagnostics and therapeutics company based in Malvern, Pennsylvania, dedicated to improving the detection, diagnosis, treatment and life-long management of patients living with chronic, eosinophil-related inflammatory diseases. Through the licensing, development and commercialization of novel technologies, NexEos Bio is bringing new tools and therapies to market that address the unmet needs of patients suffering from eosinophil-related diseases.

Contacts

For more Information, please send inquiries to: [email protected]

Market Opportunity
NuNet Logo
NuNet Price(NTX)
$0.002664
$0.002664$0.002664
-2.56%
USD
NuNet (NTX) Live Price Chart

World Cup Combo: Aim for 200x

World Cup Combo: Aim for 200xWorld Cup Combo: Aim for 200x

Combine up to 20 World Cup matches in one order

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Synopsys (SNPS) Stock Climbs on Murata Simulation Model Partnership

Synopsys (SNPS) Stock Climbs on Murata Simulation Model Partnership

Synopsys (SNPS) stock rises as Murata Manufacturing expands access to HFSS and Icepak simulation models for faster electromagnetic and thermal analysis. The post
Share
Blockonomi2026/06/16 19:46
Hyperscale Data (GPUS) Stock Retreats After 77% Rally on Massive AI Data Center Agreement

Hyperscale Data (GPUS) Stock Retreats After 77% Rally on Massive AI Data Center Agreement

Hyperscale Data (GPUS) stock retreats 7% after Monday's 77% surge. Company negotiating 20MW AI deal in Michigan valued over $1B, planning Bitcoin exit. The post
Share
Blockonomi2026/06/16 20:35
Franklin Templeton CEO Dismisses 50bps Rate Cut Ahead FOMC

Franklin Templeton CEO Dismisses 50bps Rate Cut Ahead FOMC

The post Franklin Templeton CEO Dismisses 50bps Rate Cut Ahead FOMC appeared on BitcoinEthereumNews.com. Franklin Templeton CEO Jenny Johnson has weighed in on whether the Federal Reserve should make a 25 basis points (bps) Fed rate cut or 50 bps cut. This comes ahead of the Fed decision today at today’s FOMC meeting, with the market pricing in a 25 bps cut. Bitcoin and the broader crypto market are currently trading flat ahead of the rate cut decision. Franklin Templeton CEO Weighs In On Potential FOMC Decision In a CNBC interview, Jenny Johnson said that she expects the Fed to make a 25 bps cut today instead of a 50 bps cut. She acknowledged the jobs data, which suggested that the labor market is weakening. However, she noted that this data is backward-looking, indicating that it doesn’t show the current state of the economy. She alluded to the wage growth, which she remarked is an indication of a robust labor market. She added that retail sales are up and that consumers are still spending, despite inflation being sticky at 3%, which makes a case for why the FOMC should opt against a 50-basis-point Fed rate cut. In line with this, the Franklin Templeton CEO said that she would go with a 25 bps rate cut if she were Jerome Powell. She remarked that the Fed still has the October and December FOMC meetings to make further cuts if the incoming data warrants it. Johnson also asserted that the data show a robust economy. However, she noted that there can’t be an argument for no Fed rate cut since Powell already signaled at Jackson Hole that they were likely to lower interest rates at this meeting due to concerns over a weakening labor market. Notably, her comment comes as experts argue for both sides on why the Fed should make a 25 bps cut or…
Share
BitcoinEthereumNews2025/09/18 00:36

Score Your Share of 50K USDT

Score Your Share of 50K USDTScore Your Share of 50K USDT

Complete DEX+ tasks to unlock the Champion Wheel